Moore Capital Management’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-150,000
Closed -$24.6M 779
2025
Q4
$24.6M Buy
150,000
+5,000
+3% +$783K 0.35% 66
2025
Q3
$19.4M Buy
+145,000
New +$17.6M 0.27% 86
2024
Q3
Sell
-50,000
Closed -$6.3M 543
2024
Q2
$6.3M Buy
+50,000
New +$7.84M 0.11% 184
2024
Q1
Sell
-35,000
Closed -$6.29M 516
2023
Q4
$6.29M Buy
35,000
+10,000
+40% +$1.56M 0.11% 132
2023
Q3
$3.98M Buy
+25,000
New +$4.09M 0.07% 191

Other funds holding RGEN

Moore Capital Management's RGEN Position: Q1 2026 in Review

Moore Capital Management sold out of Repligen (RGEN) in Q1 2026, closing a stake of 150,000 shares — an estimated $24.6M sold.

Moore Capital Management first reported a position in RGEN in Q3 2023 and held it in 5 quarters. The position peaked at $24.6M in Q4 2025. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

  • Moore Capital Management reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
  • Moore Capital Management sold 150,000 Repligen shares in Q1 2026, an estimated $24.6M.
  • Moore Capital Management first reported a position in Repligen in Q3 2023 and held it in 5 quarters.
  • Moore Capital Management's Repligen position peaked at $24.6M in Q4 2025.
  • 441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.